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Abstract
Background: Development of prognostic models enables identification of variables that are influential in
predicting patient outcome and the use of these multiple risk factors in a systematic, reproducible way according
to evidence based methods. The reliability of models depends on informed use of statistical methods, in
combination with prior knowledge of disease. We reviewed published articles to assess reporting and methods
used to develop new prognostic models in cancer.
Methods: We developed a systematic search string and identified articles from PubMed. Forty-seven articles were
included that satisfied the following inclusion criteria: published in 2005; aiming to predict patient outcome;
presenting new prognostic models in cancer with outcome time to an event and including a combination of at
least two separate variables; and analysing data using multivariable analysis suitable for time to event data.
Results: In 47 studies, prospective cohort or randomised controlled trial data were used for model development in
only 33% (15) of studies. In 30% (14) of the studies insufficient data were available, having fewer than 10 events
per variable (EPV) used in model development. EPV could not be calculated in a further 40% (19) of the studies.
The coding of candidate variables was only reported in 68% (32) of the studies. Although use of continuous
variables was reported in all studies, only one article reported using recommended methods of retaining all these
variables as continuous without categorisation. Statistical methods for selection of variables in the multivariate
modelling were often flawed. A method that is not recommended, namely, using statistical significance in
univariate analysis as a pre-screening test to select variables for inclusion in the multivariate model, was applied in
48% (21) of the studies.
Conclusions: We found that published prognostic models are often characterised by both use of inappropriate
methods for development of multivariable models and poor reporting. In addition, models are limited by the lack
of studies based on prospective data of sufficient sample size to avoid overfitting. The use of poor methods
compromises the reliability of prognostic models developed to provide objective probability estimates to
complement clinical intuition of the physician and guidelines.
Background
Prognosis is central to medicine. Clinicians use patient
and disease characteristics to inform patient treatment
and predict patient outcome. Development of prognostic
models enables identification of variables that are influ-
ential in predicting patient outcome and the use of
these multiple risk factors in a systematic, reproducible
way according to evidence based methods [1].
The goal of a prognostic model is to provide quantita-
tive knowledge about the probability of outcomes in a
defined patient population for patients with different
characteristics [2]. With a multivariable model, predict-
ing a patient’s future outcome can be made using com-
binations of multiple patient risk factors.
Models are ideally developed based on a combination
of prior knowledge of the disease with judicious and
informed use of statistical methods. Many of the multi-
ple steps involved to develop a prognostic model can
lead to flawed or biased models if used without good
statistical understanding.
This article examines the methods used in developing
prognostic models by a systematic review of 47 pub-
lished articles including prognostic models where the
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model as a combination of two or more independent
risk factors to predict patient outcome. We focussed on
study design, definition of outcomes, coding of variables
and statistical methods used to develop the model. We
have set out findings in the context of the methodologi-
cal literature in which the impact of the different meth-
ods on model predictions has been studied. Although
there are no specific guidelines on developing prognostic
models, there are some excellent books and articles pro-
viding advice on good and poor methodology [1-5].
However, our study shows widespread use of poor
methods in current studies. We aim to highlight this
and to add to the methodological literature to inform
and prompt further improvements in model building.
Methods
Literature search
We had planned a hand-search of 10 high impact cancer
journals in 2005 for our sample of articles (Journal of
the National Cancer Institute, Journal of Clinical Oncol-
ogy, International Journal of Cancer, British Journal of
Cancer, Cancer, European Journal of Cancer, Annals of
Oncology, Clinical Cancer Research, Cancer Research,
International Journal of Radiation Oncology). These
were the higher impact oncology journals identified as
publishing a reasonable number of prognostic studies
(2005 impact factors range 3.7 to 15.2). However, there
were only 11 articles that met our inclusion criteria, and
only two journals (Journal of Clinical Oncology and
Cancer) with more than one article in 2005. As we were
unable to identify our target of approximately 50 articles
in these journals, we decided to design a search string
in order to search all journals.
We used the prognostic articles identified from hand-
searching the Journal of Clinical Oncology to design our
search string (Additional file 1). We evaluated the search
string on the 2005 issues of Cancer,c o m p a r i n gt h e
number of articles found by string search and hand-
search.
A hand-search of the titles and three line journal sum-
maries of 784 articles in Cancer identified 42 articles as
potentially eligible. On reading the abstracts, 16 full
papers were read to establish eligibility, and four articles
were found to meet inclusion criteria. Using our search
string, 74 titles and abstracts were identified, 12 full
papers read and 5 articles identified that met inclusion
criteria. Use of the search string identified relevant arti-
cles with considerably less work than the hand-search. As
all articles in Cancer from the hand-search were identi-
fied with the electronic search, as well as an additional
article, the search string had adequate performance for
this study, as we wanted a good representation of rele-
vant articles rather than all possible articles. The search
string was then used to search PubMed for articles pub-
lished in 2005. There was no language restriction in our
search. Our search string is reported in Additional file 1.
Inclusion criteria
We included articles that met our inclusion criteria:
development of a prognostic model in cancer patients;
where the outcome was the time to an event; where the
aim of the research was to develop a new prognostic
model as a combination of at least two variables to pre-
dict patient outcome; and data were analysed using mul-
tivariable analysis suitable for time to event data.
Articles that included only validation of a pre-existing
model, were not published in print in 2005, or were
based on microarray, gene profiling or proteomics meth-
ods were excluded. Queries on article inclusions were
referred to second readers (PR, DA).
Validity assessment and data extraction
We aimed to assess a sample of approximately 50 arti-
cles developing prognostic models in cancer, to provide
a good descriptive review of the current literature
including a range of cancer sites, authors and journals.
We judged little further value would be obtained from a
larger sample. We assessed articles in random order
using a piloted data extraction form based on key
aspects of model design and development from the cur-
rent literature [1,3,4,6,7].
Data items extracted for this paper included: study
design, sample size, number of patients and events, out-
come definition, number and coding of variables in
model, and methods of selection of variables. In a com-
panion paper, Mallett et al [8], we report the assessment
of methods and reporting of multivariable analysis,
numerical and graphical presentation of the model, crea-
tion of prognostic index and risk groups, model discri-
mination and calibration, methods of validation, and
usability of reported model. Data extraction forms are
available from the corresponding author.
Sixteen items were extracted by duplicate data extrac-
tion by two of three reviewers (SM, SD, RW) with refer-
ence to a third reader where necessary. One reviewer
(SM) assessed all articles and all items. For the three
items on methods of variable selection, data were
extracted by one reader (SM). If more than one model
was presented in an article, the first model reported in
title, abstract or text was selected.
Results
Literature search
Articles on prognostic models are hard to identify in
electronic bibliographic databases as there is no stan-
dard medical subject heading from the U.S. National
Library of Medicine’s controlled vocabulary (MeSH
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m i s e dc o n t r o l l e dt r i a l s( R C T )a n dn os t a n d a r dn o m e n -
clature. Several search strings have been developed
[9-11] but other studies have used hand-searching [12].
Our search string selected 2,076 articles from 681,530
articles with subject MeSH heading of neoplasm pub-
lished in 2005, of which 47 met inclusion criteria for
this study (Figure 1) [13-59]. The yield of articles identi-
fied in the search string that met our study inclusion
criteria was 2.3%, higher than alternative search strings.
The performance of other prognostic search strings
to identify relevant articles is shown in Additional file 2.
In the 47 articles included in our study, prognostic
models were developed for the following cancer
sites: urological (ten articles); breast (seven); haematolo-
gical malignancies (six); upper gastrointestinal
and pancreas (five); prostate (five); bone metastasis
(five); lung (three); head and neck (two); colorectal
(one); skin (one); ovary (one); and bone and soft tissue
(one).
Figure 1 Flowchart of articles.
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Across 16 data extraction items relating to reporting of
model performance measures, there was agreement
between readers for 82% of items. Thirty-eight percent
of the differences were caused by ambiguities in the arti-
cles, often due to difficulties in extracting from the arti-
cles the numbers of variables, patients or events used in
the model.
Study design
The best study design to use for development of a prognos-
tic model is a prospective cohort study [2], where baseline
variables can be measured for all patients and selection bias
due to incomplete availability of data or archival samples
can be avoided [60]. Randomised controlled trial study
designs can be appropriate if eligibility criteria are not too
restrictive so as to lessen transportability, and if the sample
size assessed by the number of events is adequate. For ran-
domised controlled trials where there is a treatment effect,
it is recommended that the treatment arm is included
among the predictor variables [2].
In 21% (10) of articles models were based on prospec-
tive cohorts [16,21,22,26,34,43,45,46,56,59] (Table 1),
two of which were based on phase II trials [16,45]. Six
of these studies reported the same number of eligible
a n di n c l u d e dp a t i e n t s .P a t i ents recruited from RCTs in
11% (5) of the studies [14,38,40,44,47]. In three RCTs
researchers reported there was no significant treatment
effect [14,40,44] and in one study it was explicitly stated
that treatment arm was not used as a variable for this
reason [40]. Sixty-eight percent (32) of the studies used
a retrospective cohort design from clinical records. Ten
of these studies had the same number of eligible
patients as included patients, suggesting that complete
patient data were an unspecified inclusion criterion
[24,27,30-32,36,38,48,51,55]. In one article authors ana-
lysed three sets of data separately, two from RCTs and
one from retrospective database records [38].
Number of patients meeting inclusion criteria
The reporting of the number of patients meeting inclu-
sion criteria, as opposed to those selected for inclusion
in the analysis, can be helpful in assessing the potential
for selection bias in retrospective studies. The represen-
tativeness of the patient sample cannot be judged if data
availability is used as an eligibility criterion [12].
In 36% (17) of the studies, authors reported a differ-
ence in the number of patients meeting inclusion cri-
teria from those included in the study. In 36% (17) of
the studies the number of patients was the same. This
was highly suggestive that inclusion criteria included
availability of all prognostic variables, except perhaps for
two studies where RCT study data with no exclusions
had been used [25,40]. In 28% (14) of the studies the
number of patients or events that were eligible for the
study was either not reported or was unclear.
Number of patients and events included in analysis
The number of patients and the number of outcome
events in the patient population used to develop a prog-
nostic model are key study det a i l st h a ti ti sc r i t i c a lt o
report. Although the number of patients recruited to a
study is always important to know, the statistical
strength of a prognostic study is driven by the number
of events and by the prognostic ability of the individual
predictors.
The number of patients included in the analysis was
clearly reported in 96% (45) of the studies. Of the other
two studies, it was reported in one study that the patient
population had been split into development and valida-
tion datasets but how many were in each dataset was
not reported [13,26].
The median number of patients included in analysis
was 342 (IQR 130 to 684, n = 45) for model develop-
ment. The number of events included in the analysis
was not reported in 30% (14) of the studies. In the stu-
dies where it was reported, the median number of out-
come events was 110 (IQR 61 to 230, n = 33).
Sample size and events per variable
Ac o m m o n l yu s e drule of thumb to judge sample sizes
for developing prognostic models is the recommenda-
tion of at least 10 events per variable. This rule is based
Table 1 Study design and size
% (n = 47) articles
Study design
RCT* 11 (5)
Prospective cohort study 21 (10)
Database or other retrospective cohort 68 (32)
Reason for sample size
No reason given 77 (36)
Justified time interval (clinical or
technology)
4 (2)
Trial size (RCT or cohort) 19 (9)
Power calculation reported 0 (0)
Median (IQR)
[range]
Eligible for study:
Number of patients (n = 35) 403 (148 to 833)
Number of events (n = 20) 112 (62 to 289)
Included in analysis:
Number of patients (n = 45) 342 (130 to 684)
Number of events (n = 33) 110 (61 to 230)
Number of events per candidate variable
(n = 28)
10 (5 to 33) [2 to 95]
*RCT randomised controlled trial
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individual variables in prognostic model [61-66]. Many
prognostic studies have unsuitably small sample sizes,
identified easily by the rule of thumb as having fewer
than 10 events per variable used in model development.
Use of variable selection procedures in studies with
small sample sizes results in models with biased selec-
tion of variables, unreliable coefficients and inaccurate
predictions [3]. Despite the difficulties in calculating sui-
table sample sizes with power calculations, studies
should report their justification for the choice of sample
size.
In 77% (36) of the studies no justification was given
for the sample size. In 23% (11) of the studies reasons
were given for sample size; with one exception all these
s t u d i e sw e r eR C T so rp r o s p e c t i v ec o h o r t s
[14,16,25,26,38,40,43-45,54,56]. In two studies research-
ers used a justified time interval based on a change in
treatment or chemotherapy regimen [43,54]. Two trials
used a subset of disease categories, one from an RCT
and one from a time justified database [25,54]. None of
the studies included a power calculation.
For the 28 studies (60% of studies) where it could be
calculated, the median number of events per candidate
model variable (EPV) was 10 (IQR 5 to 33, range 2 to
95). In 30% (14) of studies too few events were reported
for the number of variables analysed in the model, indi-
cating insufficient data for reliable interpretation of
model findings. In 40% (19) of the studies there was
insufficient information to calculate study EPV.
Definition and number of outcomes
Clear definition of the study outcomes in prognostic
research is critical for a clear interpretation of the
model. Studies in breast cancer [67] and treatment of
bone metastasis [68] have found that outcome defini-
tions are often unclear and inconsistent between studies.
D i s e a s ef r e es u r v i v a l( D F S )i sparticularly inconsistent
and can include any or all of local, regional, distant
recurrence and death [67].
The use of study outcomes defined ap r i o r iis the
recommended standard in order to avoid any suggestion
of selective reporting of model outcomes based on study
results. Articles where a large number of study out-
comes are examined have potential for bias in the selec-
tion of outcomes for multivariable analysis and the
prognostic index. A review of randomized controlled
trials identified selective outcome reporting where the
prespecified primary outcome of event -free survival was
omitted from published reports [69].
Overall survival was examined as the primary outcome
in 66% (31) of the studies (Table 2). DFS (or the related
outcomes of event-free survival local regional recurrence
etc.) were examined in 34% (16) of the studies. A clear
definition of the outcomes examined in the multivari-
able analysis was included in 60% (28) of studies. In 40%
of the articles the outcomes were not clearly defined; in
30% (14) of studies it was unclear whether all deaths or
only cancer deaths were included in overall survival and
in 10% (5) of the studies whether death was included in
DFS outcomes.
In our study there was a median of one outcome per
article (IQR one to two; range one to five; Table 2). In
13 studies researchers reported more than one outcome,
with three or more outcomes examined in four studies.
The median number of outcomes included in multivari-
able analyses was one (IQR one to one; range one to
five). In 13 studies researchers used more than one out-
come in multivariable analyses, in three studies
researchers used three or more outcomes in multivari-
able analyses. In two studies it was unclear how many
outcomes were used in multivariable analyses [32,33],
but two and three outcomes were included in these
papers.
Coding of variables
Multivariable analysis may be performed using a mix-
ture of continuous, categorical and binary candidate
variables. The methods used to handle the continuous
and categorical variables may strongly affect the final
prognostic model, both in terms of variables selected by
their statistical significance and the coefficient values for
included variables [5].
The practice of dichotomising continuous variables is
not recommended, as it is an extreme form of rounding
that causes loss of information and statistical power,
equivalent to losing a third of the data [70]. In addition
it results in unrealistic steps in the predicted risk, with
Table 2 Outcomes and definitions
% (n = 47) articles
Primary outcome
Overall survival 66 (31)
Disease free survival (DFS) 34 (16)
Definition of outcomes
Overall survival (n = 31)
Explicitly death from any cause 15 (7)
Cancer death only 21 (10)
Type of death unclear 30 (14)
Disease free survival (n = 16)
DFS including death* 10 (5)
DFS not including death 13 (6)
DFS but unclear if includes death 10 (5)
Multivariable outcome clearly defined‡ 60 (28)
* In one study it was not clear if DFS deaths included all deaths or only
cancer specific deaths
‡ In two articles it was unclear how many outcomes were examined
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different levels of risk [70]. Dichotomising at the median
value is problematic as each study will have a different
cutpoint and cutpoints are data driven, that is, chosen
using the data itself [71]. Furthermore choice of an opti-
mal or minimal p-value cutpoint is even worse [72].
Despite these and other disadvantages, dichotomisation
of continuous variables is very frequently used in devel-
oping prognostic models. Classification of continuous
variables into three or more groups as ordinal variables
will similarly affect variables selected by significance in a
prognostic model.
Continuous candidate variables were frequently con-
verted to categorical or binary variables. All studies
included at least one continuous candidate variable in
model development. Only one article kept all continu-
ous variables as continuous (Table 3), whereas 19% (9)
categorised at least one continuous variable, 51% (24)
categorised all continuous variables and in 28% (13) of
the studies it was unclear how continuous variables
were handled due to poor reporting.
Clear and transparent reporting of how variables are
coded in the model is necessary so the model can be
repeated and applied in clinical practice [73]. The cod-
ing of all the candidate variables used in model develop-
ment was reported in 68% (32) of the studies (Table 3)
and the coding for the variables in the final model was
reported in 70% (33) of the studies.
Selection of variables in multivariable analysis
A description of patient demographics, disease severity,
laboratory investigations and treatment is important in
understanding the clinical population used to develop a
prognostic model. Many of these characteristics are
used as variables in development of the prognostic
model, with statistical modelling used to select the most
influential variables for a final model.
There is no consensus on the best methods for select-
ing variables for a final model, although some methods
are particularly cautioned against, such as inclusion or
exclusion of variables based on univariable analysis [4].
Selection conditional on univariable tests in small sam-
ple sizes is likely to introduce error as the correlation
between prognostic variables is not properly controlled
for [74]. An additional, but lesser, concern is that prog-
nostic variables are eliminated which have a weak asso-
ciation with study outcome or are by chance not
prognostic in the particular sample of patients.
It is recommended that prognostic risk factors which
have clinical credibility and are already well established
in the literature are retained in models. Biases are gen-
erated by the method of selection and the p-values used
to set selection limits for inclusion and exclusion of
variables [3-5]. If automated variable selection methods
are to be used, then backward elimination is preferred
to forward selection as it starts with a full model
and considers a wider range of possible best models,
and also is a better method where variables are corre-
lated [5].
We assessed the methods used for selection of vari-
ables in the 43 studies using Cox models for develop-
ment of a prognostic index (Table 4). Twenty-six
percent (11) of Cox models included all variables in the
multivariable analysis [13,28,33,35-37,39,40,46,50,56].
Fifteen percent (6) of the studies used non statistical
reasons, including information from published literature
and investigators’ choice to select variables for multivari-
able analysis [16,23,26,27,38,44]. Specific reasons to
exclude variables were based on collinearity with other
variables, due to missing data or due to variables relat-
ing to treatment where the model was to predict regard-
less of treatment. In 49% (21) of the studies, researchers
used a method that is not recommended, which consists
of a conditional pre-test for statistical significance in
univariable analysis. In 11% (5) of the models, the
method of variable selection was not reported or was
unclear.
The statistical modelling methods used within the
multivariable models were reported in only 33% (10) of
the studies (Table 4). In one model the selection
method started with fixed ap r i o r ivariables and added
further variables [26], a method likely to be appropriate
where there is much established clinical knowledge.
Table 3 Variables in multivariable analysis
% (n = 47)
articles
Coding of variables in model
Coding explicit for all candidate variables 68 (32)
Coding explicit for all variables in final model‡ 70 (33)
Coding of continuous candidate variables
All continuous 2 (1)
All categorised/dichotomised 51 (24)
Combination of continuous and categorised
variables
19 (9)
No continuous candidate variables 0 (0)
Unclear/not reported 28 (13)
Median (IQR)
(range)
Number of variables
Candidates used to develop model* (n = 46) 11 (7 to 14)
(2 to 27)
Included in final model** (n = 44) 4 (3 to 6)
(2 to 12)
‡ Two papers could not be assessed as the final model was unclear.
* In four articles variables were excluded where it was unclear if these were
candidate variables. In one article the number of candidate variables was
completely unclear
** Three articles could not be included: two because the final model was not
presented in the paper, one because it was not clear which of the alternative
models in the paper was the final model.
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and the less recommended forward selection in 5% (2).
Fourteen percent (6) of the prognostic models were
based on a multivariable analysis in which all candidate
variables were included regardless of their statistical sig-
nificance. We note that variables will almost certainly
have been selected from those clinically recorded, so it
is unlikely variables are in reality completely unselected
[5]. In 65% (28) of the models researchers retained only
variables statistically significant in multivariable model-
ling, with one model also retaining variables established
as important in the previous literature [38]. One model
was based on variables selected using goodness of fit of
the model as a whole [51], an alternative method to
selecting by P-value of individual variables [3].
In two models researchers retained only significant
variables in the final model, but then added to or
removed variables from the prognostic score without
repeating the model fit, based on investigators’ choice
[29,58]. The authors of two articles appear confused as
to the purpose of their models, and included adjustment
for six to nine variables in a footnote to their model,
while retaining only two significant variables in the pre-
dictive score [18,43]. Effectively the adjusted variables
are altering the coefficient values of the variables in the
score, but are not available to readers. In 7% (3) of the
models authors did not report methods used to include
variables in the final model [44,55,57].
Overall 87% (37) of models were developed using
selection of variables during modelling (Table 3), from a
median of 11 candidate variables (IQR 7 to 14; range
2 to 27; n = 46) used to develop models to a median of
four variables included (IQR 3 to 6, range 2 to 12,
n = 44) in the final multivariable model (Table 3). Cal-
culation of the number of final variables in the model
excluded four studies, two studies where the final model
was not reported and two where the final model was
not clear.
Examples of good methods and reporting
Although the quality of the articles was generally disap-
pointing, we particularly wish to highlight two articles
using good methods and good reporting [38,40]. These
two studies deserve mentioning as authors included:
good study design for developing prognostic models e.g.
RCTs; sufficient sample sizes to allow reliable model
development (EPV values of over 40); the coding of vari-
ables was clear and not all continuous variables
Table 4 Selection of variables in multivariable analysis
% (n = 43*)
Selection of variables for inclusion in multivariable analysis
All candidate variables used (no selection) 26 (11)
All candidate variables apart from a few with contra indications** 5 (2)
Without statistical analysis
Previous literature 5 (2)
Previous literature and few variables by investigator choice 5 (2)
By statistical analysis
Screening by univariable analysis - only significant variables 37 (16)
Screening by univariable analysis - significant variables and investigator choice 11 (5)
Unclear/Not reported 11 (5)
Statistical modelling methods used within multivariable analysis
A priori variables fixed, others added 2 (1)
Backward elimination 14 (6)
Forward selection 5 (2)
Other (pairwise multiple testing for categories of variables) 2 (1)
Unclear/Not reported 77 (33)
Methods for inclusion of variables in final model and prognostic index
No selection. All variables kept in model 14 (6)
Retain only significant variables based on P-value 65 (28)
Retain significant variables plus variables based on previous literature 2 (1)
Retain all variables but alter prognostic score after model to include only significant variables and adjust for other variables 5 (2)
Retain only significant variables but alter prognostic score after final model 5 (2)
Retain based on model goodness of fit 2 (1)
Unclear/Not reported 7 (3)
* Excluded four studies using recursive partitioning analysis and artificial neural network models
** Contra indications reported as reasons for exclusion of variables were missing data, collinearity and treatment indicator
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cients for the final model; reasonable strategies for selec-
tion of variables were used; and proportional hazards
assumptions tested for the Cox model. The reporting of
the definition of deaths included in overall survival
could have been clarified. Also, it could have been noted
whether the use of complete cases in multivariable ana-
lysis was likely to have introduced selection bias in these
RCT patient populations. These articles [38,40] in com-
bination with published guidelines on development of
prognostic models [1-5,61] may be useful to researchers
developing prognostic models.
Discussion
In this article we have highlighted the methods currently
used to develop prognostic models for clinical predic-
tions about patients with cancer, and the poor reporting
o ft h o s em e t h o d s .T h eq u a l i t yo fp r o g n o s t i cm o d e l s
depends on study design and statistical methods.
Researchers should understand the assumptions inher-
ent in the statistical methods and follow sound princi-
ples to ensure that methods are appropriately applied
and reported [75].
Most prognostic models, 68% in this study, are based
on retrospective databases which have many inherent
biases, often due to patchy availability of patient infor-
mation [60]. The lack of studies specifically designed to
meet patients’ and healthcare professionals’ needs for
prognostic information is highlighted by the fact that
none of the studies in our sample justified the chosen
sample size.
The paucity of prognostic models based on prospec-
tive cohorts is a serious limitation in the generalisability
and usefulness of quantitative information valued by
both patients and healthcare professionals. Randomised
controlled trials could potentially provide good datasets
for model development if they include sufficiently
detailed baseline data andc o v e r a g eo ft h er e l e v a n t
patient population.
Fifty percent (14 of 28) of the studies, where EPV
could be calculated, had fewer than 10 events per candi-
date variable (EPV) used in model development, with
only eight studies having over 20 events per variable. In
at least half of these models it is probable that many of
the variables selected as statistically significant would
not be selected if the modelling was repeated in a simi-
lar sample, due to the low number of events in the sam-
ple and the investigator choice of variables and methods
[5,63]. It follows that many of these models are unreli-
able. In any case, all newly proposed models need inde-
pendent validation before being considered for clinical
use [76]. Other reviewers of prognostic studies have also
found a large number of both Cox and logistic models
with <10 EPV [65,77].
Poor reporting was evident in all aspects of model
development, from descriptions of the patient data to
statistical modelling methods, including details of the
multiple steps where bias or errors can be introduced
(Table 4). In only 60% (28) of the studies did authors
include clear reporting of outcome events used in the
model (Table 2). Lack of transparency in the definition
of outcomes has been shown to lead to lack of transpar-
ency and transportability in studies [67].
Coding of variables used in model development and
methods used to select variables in the multivariable
models are also critical to the reliability of modelling
methods. Continuous variables should be retained in the
model as continuous measures, as otherwise information
is lost and results can be biased by choice of cutpoints
used in variable categorisation. Fractional polynomial
functions [5] and splines are recommended methods for
modelling continuous variables that have nonlinear rela-
tionships with the outcome variable. In only one article
[13] were all candidate continuous variables kept as con-
tinuous in developing the model (Table 3). Categorisation
was applied at least to some continuous variables in 70%
of models. In about a third of the models it was unclear
about how continuous variables were coded. Poor report-
ing of coding of variables in both Cox and logistic models
has also been reported in other studies [65,78,79].
There was evidence that poor methods are widely used
for the selection of variables for models, as a method that
is not recommended was used in 48% of studies. This
method was pre-screening of variables for model inclu-
sion based on univariable analysis [4]. Univariable screen-
ing can lead to rejection of variables that could have been
influential prognostic factors [74], especially with small
sample sizes and in the presence of collinearity between
variables. Poor reporting of variable selection has been
described similarly in other studies [65,80].
Although in this study we limited attention to prog-
nostic models in cancer, the problems identified are not
specific to cancer. These models had a time to event
outcome, and Cox regression modelling was used in
almost all studies. However, many issues identified here
are similar to those found in logistic regression.
This research, together with the companion article
Mallett et al [8], highlights poor methods and reporting
in the development of prognostic models in published
articles. There is a need for researchers to use more
appropriate methods and to report their studies more
effectively. In addition, peer reviewers and journal edi-
tors need to be more demanding in their assessment of
articles for publication.
Conclusions
In conclusion we found that published prognostic mod-
els are often characterised by both use of poor methods
Mallett et al. BMC Medicine 2010, 8:20
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Page 8 of 11for development of multivariable models and poor
reporting. In addition, models are limited by the lack of
studies based on prospective data of sufficient sample
size to avoid overfitting.
Prognostic models are developed to provide objective
probability estimates to complement clinical intuition of
the physician and guidelines [81]. Many published prog-
nostic models have been developed using poor metho-
dological choices that may adversely affect model
reliability.
Additional file 1: Search string Mallett 2009. This file includes the
search strategy and Pubmed search string format.
Additional file 2: Comparison of prognostic search strings. Part (A)
includes the performance of hand search and search string. Part (B) is a
comparison of the included articles found with other prognostic search
strings.
Abbreviations
DFS: disease free survival; EPV: events per variable; IQR: interquartile range;
MeSH: medical subject heading from the U.S. National Library of Medicine’s
controlled vocabulary; NLM: National Library of Medicine; RCT: randomised
controlled trial.
Acknowledgements
We thank Gary Collins for helpful comments on the manuscript. SM, DGA,
RW and SD are supported by Cancer Research UK. PR is supported by the
UK Medical Research Council (U.1228.06.001.00002.01).
Author details
1Centre for Statistics in Medicine, University of Oxford, Linton Rd OX2 6UD,
Oxford, UK.
2MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA,
UK.
Authors’ contributions
SM contributed to the design, carried out data extraction on all articles and
items, compiled results and drafted the manuscript. PR and DGA contributed
to the design and drafting of the article. RW and SD carried out duplicate
data extraction for some data items and commented on the manuscript.
Authors’ informations
All authors are medical statisticians.
Competing interests
The authors declare that they have no competing interests.
Received: 19 February 2010 Accepted: 30 March 2010
Published: 30 March 2010
References
1. Steyerberg EW: Clinical prediction models New York: Springer 2008.
2. Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG: Prognosis
and prognostic research: what, why, and how? BMJ 2009, 338:b375.
3. Harrell FE Jr: Regression Modeling Strategies:with applications to linear
models, logistic regression and survival analysis. New York: Springer-
Verlag 2001.
4. Royston P, Moons KG, Altman DG, Vergouwe Y: Prognosis and prognostic
research: developing a prognostic model. BMJ 2009, 338:b604.
5. Royston P, Sauerbrei W: Multivariable Model-Building: A Pragmatic
Approach To Regression Analysis Based On Fractional Polynomials For
Modelling Continuous Variables. John Wiley & Sons Ltd, Chicester UK, 1
2008.
6. Altman DG, Royston P: What do we mean by validating a prognostic
model? Stat Med 2000, 19:453-473.
7. Altman DG: Prognostic models: a methodological framework and review
of models for breast cancer. Cancer Invest 2009, 27:235-243.
8. Mallett S, Royston P, Waters R, Dutton S, Altman D: Reporting performance
of prognostic models in cancer: a review. BMC Medicine 2010, 8:21.
9. Ingui BJ, Rogers MA: Searching for clinical prediction rules in MEDLINE. J
Am Med Inform Assoc 2001, 8:391-397.
10. Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J,
Gray A, Harris A, Johnston K, Lodge M: Cost-effectiveness of using
prognostic information to select women with breast cancer for adjuvant
systemic therapy. Health Technol Assess 2006, 10:iii-xi, 1.
11. Wilczynski NL, Haynes RB: Developing optimal search strategies for
detecting clinically sound prognostic studies in MEDLINE: an analytic
survey. BMC Med 2004, 2:23.
12. Burton A, Altman DG: Missing covariate data within cancer prognostic
studies: a review of current reporting and proposed guidelines. Br J
Cancer 2004, 91:4-8.
13. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Belldegrun AS,
Horvath S, Figlin RA: Using tumor markers to predict the survival of
patients with metastatic renal cell carcinoma. J Urol 2005, 173:1496-1501.
14. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH: Clinical model to
predict survival in chemonaive patients with advanced non-small-cell
lung cancer treated with third-generation chemotherapy regimens
based on eastern cooperative oncology group data. J Clin Oncol 2005,
23:175-183.
15. Jerez JM, Franco L, Alba E, Llombart-Cussac A, Lluch A, Ribelles N,
Munarriz B, Martin M: Improvement of breast cancer relapse prediction in
high risk intervals using artificial neural networks. Breast Cancer Res Treat
2005, 94:265-272.
16. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P,
Bukowski R: Validation and extension of the Memorial Sloan-Kettering
prognostic factors model for survival in patients with previously
untreated metastatic renal cell carcinoma. J Clin Oncol 2005, 23:832-841.
17. North RB, LaRocca VR, Schwartz J, North CA, Zahurak M, Davis RF,
McAfee PC: Surgical management of spinal metastases: analysis of
prognostic factors during a 10-year experience. J Neurosurg Spine 2005,
2:564-573.
18. Smith BD, Smith GL, Cooper DL, Wilson LD: The cutaneous B-cell
lymphoma prognostic index: a novel prognostic index derived from a
population-based registry. J Clin Oncol 2005, 23:3390-3395.
19. Solsona E, Iborra I, Dumont R, Rubio J, Casanova JL, Almenar S: Risk groups
in patients with bladder cancer treated with radical cystectomy:
statistical and clinical model improving homogeneity. J Urol 2005,
174:1226-1230.
20. Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED,
Merchan JR, Blute ML: A scoring algorithm to predict survival for patients
with metastatic clear cell renal cell carcinoma: a stratification tool for
prospective clinical trials. J Urol 2005, 174:1759-1763.
21. Liao CS, Yang KC, Yen MF, Hsiu-Hsi CT: Time-varying predictors for clinical
surveillance of small hepatocellular carcinoma. Cancer J 2005, 11:226-233.
22. Khaled H, El Hattab O, Moneim DA, Kassem HA, Morsi A, Sherif G,
Darwish T, Gaafar R: A prognostic index (bladder prognostic index) for
bilharzial-related invasive bladder cancer. Urol Oncol 2005, 23:254-260.
23. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA,
DiBlasio CJ, Reuther A, Klein EA, Kattan MW: Postoperative nomogram
predicting the 10-year probability of prostate cancer recurrence after
radical prostatectomy. J Clin Oncol 2005, 23:7005-7012.
24. Lin YC, Chen SC, Chang HK, Hsueh S, Tsai CS, Lo YF, Hwang TL, Chen MF:
Identifying good prognosis group of breast cancer patients with 1-3
positive axillary nodes for adjuvant cyclophosphamide, methotrexate
and 5-fluorouracil (CMF) chemotherapy. Jpn J Clin Oncol 2005, 35:514-519.
25. Linden van der YM, Dijkstra SP, Vonk EJ, Marijnen CA, Leer JW: Prediction
of survival in patients with metastases in the spinal column: results
based on a randomized trial of radiotherapy. Cancer 2005, 103:320-328.
26. Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU,
Kau SW, Fornage B, Sahin A, Broglio K, Singletary SE, Valero V: Outcome
after pathologic complete eradication of cytologically proven breast
cancer axillary node metastases following primary chemotherapy. J Clin
Oncol 2005, 23:9304-9311.
27. Stracci F, La Rosa F, Falsettini E, Ricci E, Aristei C, Bellezza G, Bolis GB,
Fenocchio D, Gori S, Rulli A, Mastrandrea V: A population survival model
for breast cancer. Breast 2005, 14:94-102.
Mallett et al. BMC Medicine 2010, 8:20
http://www.biomedcentral.com/1741-7015/8/20
Page 9 of 1128. Kikuchi E, Horiguchi Y, Nakashima J, Hatakeyama N, Matsumoto M,
Nishiyama T, Murai M: Lymphovascular invasion independently predicts
increased disease specific survival in patients with transitional cell
carcinoma of the upper urinary tract. J Urol 2005, 174:2120-2123.
29. Kato H, Yoshimatsu K, Ishibashi K, Watanabe K, Shiozawa S, Tsuchiya A,
Yamada R, Sakamoto T, Haga S: A new staging system for colorectal
carcinoma with liver metastasis. Anticancer Res 2005, 25:1251-1255.
30. Truong PT, Lesperance M, Culhaci A, Kader HA, Speers CH, Olivotto IA:
Patient subsets with T1-T2, node-negative breast cancer at high
locoregional recurrence risk after mastectomy. Int J Radiat Oncol Biol Phys
2005, 62:175-182.
31. Peccatori J, Barkholt L, Demirer T, Sormani MP, Bruzzi P, Ciceri F, Zambelli A,
Da Prada GA, Pedrazzoli P, Siena S, Massenkeil G, Martino R, Lenhoff S,
Corradini P, Rosti G, Ringden O, Bregni M, Niederwieser D: Prognostic
factors for survival in patients with advanced renal cell carcinoma
undergoing nonmyeloablative allogeneic stem cell transplantation.
Cancer 2005, 104:2099-2103.
32. Hahn T, Benekli M, Wong C, Moysich KB, Hyland A, Michalek AM, Alam A,
Baer MR, Bambach B, Czuczman MS, Wetzler M, Becker JL, McCarthy PL: A
prognostic model for prolonged event-free survival after autologous or
allogeneic blood or marrow transplantation for relapsed and refractory
Hodgkin’s disease. Bone Marrow Transplant 2005, 35:557-566.
33. Claude L, Perol D, Ray-Coquard I, Petit T, Blay JY, Carrie C, Bachelot T:
Lymphopenia: a new independent prognostic factor for survival in
patients treated with whole brain radiotherapy for brain metastases
from breast carcinoma. Radiother Oncol 2005, 76:334-339.
34. Colinet B, Jacot W, Bertrand D, Lacombe S, Bozonnat MC, Daures JP,
Pujol JL: A new simplified comorbidity score as a prognostic factor in
non-small-cell lung cancer patients: description and comparison with
the Charlson’s index. Br J Cancer 2005, 93:1098-1105.
35. Molica S, Mauro FR, Callea V, Gentile M, Giannarelli D, Lopez M, Lauria F,
Rotoli B, Montanaro M, Cortelezzi A, Liso V, Mandelli F, Foa R: A gender-
based score system predicts the clinical outcome of patients with early
B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2005, 46:553-560.
36. Matsui Y, Utsunomiya N, Ichioka K, Ueda N, Yoshimura K, Terai A, Arai Y:
Risk factors for subsequent development of bladder cancer after
primary transitional cell carcinoma of the upper urinary tract. Urology
2005, 65:279-283.
37. Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M,
McKiernan J, Russo P: A postoperative prognostic nomogram predicting
recurrence for patients with conventional clear cell renal cell carcinoma.
J Urol 2005, 173:48-51.
38. Steyerberg EW, Homs MY, Stokvis A, Essink-Bot ML, Siersema PD: Stent
placement or brachytherapy for palliation of dysphagia from esophageal
cancer: a prognostic model to guide treatment selection. Gastrointest
Endosc 2005, 62:333-340.
39. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J,
Carroll PR: The University of California, San Francisco Cancer of the
Prostate Risk Assessment score: a straightforward and reliable
preoperative predictor of disease recurrence after radical prostatectomy.
J Urol 2005, 173:1938-1942.
40. Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE,
Verdonck LF, Vellenga E, De Greef GE, Jacky E, Lelie Van der J,
Boogaerts MA, Lowenberg B: Prognostic index for adult patients with
acute myeloid leukemia in first relapse. J Clin Oncol 2005, 23:1969-1978.
41. Langendijk JA, Slotman BJ, Waal van der I, Doornaert P, Berkof J,
Leemans CR: Risk-group definition by recursive partitioning analysis of
patients with squamous cell head and neck carcinoma treated with
surgery and postoperative radiotherapy. Cancer 2005, 104:1408-1417.
42. Klemke CD, Mansmann U, Poenitz N, Dippel E, Goerdt S: Prognostic factors
and prediction of prognosis by the CTCL Severity Index in mycosis
fungoides and Sezary syndrome. Br J Dermatol 2005, 153:118-124.
43. Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, Dhillon T,
Young AM, Powles T, Gaya A, Nelson M, Stebbing J: A prognostic index for
systemic AIDS-related non-Hodgkin lymphoma treated in the era of
highly active antiretroviral therapy. Ann Intern Med 2005, 143:265-273.
44. Mariani L, Miceli R, Lusa L, Di Bartolomeo M, Bozzetti F: A modified
prognostic score for patients with curatively resected gastric cancer.
Tumori 2005, 91:221-226.
45. Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J,
Maase von der H: Elevated neutrophil and monocyte counts in
peripheral blood are associated with poor survival in patients with
metastatic melanoma: a prognostic model. Br J Cancer 2005, 93:273-278.
46. Katagiri H, Takahashi M, Wakai K, Sugiura H, Kataoka T, Nakanishi K:
Prognostic factors and a scoring system for patients with skeletal
metastasis. J Bone Joint Surg Br 2005, 87:698-703.
47. Aa van der MN, van Leenders GJ, Steyerberg EW, van Rhijn BW, Jobsis AC,
Zwarthoff EC, Kwast van der TH: A new system for substaging pT1
papillary bladder cancer: a prognostic evaluation. Hum Pathol 2005,
36:981-986.
48. Saisho T, Okusaka T, Ueno H, Morizane C, Okada S: Prognostic factors in
patients with advanced biliary tract cancer receiving chemotherapy.
Hepatogastroenterology 2005, 52:1654-1658.
49. Rubio L, Vera-Sempere FJ, Lopez-Guerrero JA, Padilla J, Moreno-Baylach MJ:
A risk model for non-small cell lung cancer using clinicopathological
variables, angiogenesis and oncoprotein expression. Anticancer Res 2005,
25:497-504.
50. Mariani L, Miceli R, Kattan MW, Brennan MF, Colecchia M, Fiore M,
Casali PG, Gronchi A: Validation and adaptation of a nomogram for
predicting the survival of patients with extremity soft tissue sarcoma
using a three-grade system. Cancer 2005, 103:402-408.
51. Tateishi R, Yoshida H, Shiina S, Imamura H, Hasegawa K, Teratani T, Obi S,
Sato S, Koike Y, Fujishima T, Makuuchi M, Omata M: Proposal of a new
prognostic model for hepatocellular carcinoma: an analysis of 403
patients. Gut 2005, 54:419-425.
52. Yildirim E: A model for predicting outcomes in patients with
differentiated thyroid cancer and model performance in comparison
with other classification systems. J Am Coll Surg 2005, 200:378-392.
53. Shulman MJ, Benaim EA: Prognostic model of event-free survival for
patients with androgen-independent prostate carcinoma. Cancer 2005,
103:2280-2286.
54. Gronlund B, Christensen IJ, Bulow-Lehnsby AL, Engelholm SA, Hansen HH,
Hogdall C: Recurrent epithelial ovarian cancer: validation and
improvement of an established prognostic index. Eur J Obstet Gynecol
Reprod Biol 2005, 123:98-106.
55. Hasebe T, Sasaki S, Imoto S, Wada N, Ishii G, Ochiai A: Primary tumour-
vessel tumour-nodal tumour classification for patients with invasive
ductal carcinoma of the breast. Br J Cancer 2005, 92:847-856.
56. Slovin SF, Wilton AS, Heller G, Scher HI: Time to detectable metastatic
disease in patients with rising prostate-specific antigen values following
surgery or radiation therapy. Clin Cancer Res 2005, 11:8669-8673.
57. Meyer JS, Alvarez C, Milikowski C, Olson N, Russo I, Russo J, Glass A,
Zehnbauer BA, Lister K, Parwaresch R: Breast carcinoma malignancy
grading by Bloom-Richardson system vs proliferation index:
reproducibility of grade and advantages of proliferation index. Mod
Pathol 2005, 18:1067-1078.
58. Froehner M, Koch R, Litz RJ, Haase M, Klenk U, Oehlschlaeger S,
Baretton GB, Wirth MP: Comparison of tumor- and comorbidity-related
predictors of mortality after radical prostatectomy. Scand J Urol Nephrol
2005, 39:449-454.
59. Nathan SS, Healey JH, Mellano D, Hoang B, Lewis I, Morris CD,
Athanasian EA, Boland PJ: Survival in patients operated on for pathologic
fracture: implications for end-of-life orthopedic care. J Clin Oncol 2005,
23:6072-6082.
60. Hoppin JA, Tolbert PE, Taylor JA, Schroeder JC, Holly EA: Potential for
selection bias with tumor tissue retrieval in molecular epidemiology
studies. Ann Epidemiol 2002, 12:1-6.
61. Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: issues in
developing models, evaluating assumptions and adequacy, and
measuring and reducing errors. Stat Med 1996, 15:361-387.
62. Altman DG, Andersen PK: Bootstrap investigation of the stability of a Cox
regression model. Stat Med 1989, 8:771-783.
63. Peduzzi P, Concato J, Feinstein AR, Holford TR: Importance of events per
independent variable in proportional hazards regression analysis. II.
Accuracy and precision of regression estimates. J Clin Epidemiol 1995,
48:1503-1510.
64. Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA: Regression modelling
strategies for improved prognostic prediction. Stat Med 1984, 3:143-152.
65. Concato J, Peduzzi P, Holford TR, Feinstein AR: Importance of events per
independent variable in proportional hazards analysis. I. Background,
goals, and general strategy. J Clin Epidemiol 1995, 48:1495-1501.
Mallett et al. BMC Medicine 2010, 8:20
http://www.biomedcentral.com/1741-7015/8/20
Page 10 of 1166. Steyerberg EW: Study design for prediction models. Clinical prediction
models New York: Springer 2008, Chapter 3.
67. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA,
Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA: Proposal for
standardized definitions for efficacy end points in adjuvant breast
cancer trials: the STEEP system. J Clin Oncol 2007, 25:2127-2132.
68. Chow E, Wu JS, Hoskin P, Coia LR, Bentzen SM, Blitzer PH: International
consensus on palliative radiotherapy endpoints for future clinical trials
in bone metastases. Radiother Oncol 2002, 64:275-280.
69. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG: Empirical
evidence for selective reporting of outcomes in randomized trials:
comparison of protocols to published articles. JAMA 2004, 291:2457-2465.
70. Royston P, Altman DG, Sauerbrei W: Dichotomizing continuous predictors
in multiple regression: a bad idea. Stat Med 2006, 25:127-141.
71. Altman DG, Royston P: The cost of dichotomising continuous variables.
BMJ 2006, 332:1080.
72. Altman DG, Lausen B, Sauerbrei W, Schumacher M: Dangers of using
“optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer
Inst 1994, 86:829-835.
73. Simon R, Altman DG: Statistical aspects of prognostic factor studies in
oncology. Br J Cancer 1994, 69:979-985.
74. Sun GW, Shook TL, Kay GL: Inappropriate use of bivariable analysis to
screen risk factors for use in multivariable analysis. J Clin Epidemiol 1996,
49:907-916.
75. Graf E, Schmoor C, Sauerbrei W, Schumacher M: Assessment and
comparison of prognostic classification schemes for survival data. Stat
Med 1999, 18:2529-2545.
76. Altman DG, Vergouwe Y, Royston P, Moons KG: Prognosis and prognostic
research: validating a prognostic model. BMJ 2009, 338:b605.
77. Ottenbacher KJ, Ottenbacher HR, Tooth L, Ostir GV: A review of two
journals found that articles using multivariable logistic regression
frequently did not report commonly recommended assumptions. J Clin
Epidemiol 2004, 57:1147-1152.
78. Hernandez AV, Vergouwe Y, Steyerberg EW: Reporting of predictive
logistic models should be based on evidence-based guidelines. Chest
2003, 124:2034-2035.
79. Mikolajczyk RT, DiSilvestro A, Zhang J: Evaluation of logistic regression
reporting in current obstetrics and gynecology literature. Obstet Gynecol
2008, 111:413-419.
80. Tetrault JM, Sauler M, Wells CK, Concato J: Reporting of multivariable
methods in the medical literature. J Investig Med 2008, 56:954-957.
81. Moons KG, Altman DG, Vergouwe Y, Royston P: Prognosis and prognostic
research: application and impact of prognostic models in clinical
practice. BMJ 2009, 338:b606.
Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.
biomedcentral.com/1741-7015/8/20/prepub
doi:10.1186/1741-7015-8-20
Cite this article as: Mallett et al.: Reporting methods in studies
developing prognostic models in cancer: a review. BMC Medicine 2010
8:20.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mallett et al. BMC Medicine 2010, 8:20
http://www.biomedcentral.com/1741-7015/8/20
Page 11 of 11